Laboratories

Urology

KEYWORDS

  • GU cancer
  • genome
  • biology

HEAD

AKAMATSU Shusuke

Professor

Researchers

LAB MEMBER

Faculty Position Researchers
ZENNAMI Kenji Associate professor Researchers
ISHIDA Shohei Lecturer Researchers
KIMURA Tomokazu Lecturer Researchers
SANO Tomoyasu Lecturer Researchers
INOUE Satoshi Assistant professor Researchers
MATSUO Kazuna Assistant clinical professor Researchers
SANO Yuta Assistant professor Researchers
HATTORI Kyosuke Assistant professor Researchers
NAGAYAMA Jun Assistant professor Researchers
TAKIKAWA Masahiro Assistant professor Researchers

CONTACT

Email urology◎med.nagoya-u.ac.jp (Please send a message after replacing "◎" mark with "@" mark. )
HP Private Page

OUTLINE

Our laboratory focuses on deciphering the mechanisms of treatment resistance, identifying novel biomarkers and therapeutic targets, and developing innovative therapies for prostate, renal, and urothelial cancers. We advance our research using a dual approach: a top-down strategy that leverages abundant clinical patient samples to identify disease-relevant molecular targets, and a bottom-up strategy that begins with in vitro validation of hypotheses arising from clinically driven questions.

RESEARCH PROJECTS

  • Overcoming therapeutic resistance in prostate cancer through single-cell sequencing–based analyses
  • Elucidation of the mechanisms of action of PARP inhibitors and development of novel combination therapies in prostate cancer
  • Transcriptomic profiling of prostate cancer using archived formalin-fixed specimens
  • Characterization of the biological features of BAP1-deficient renal cell carcinoma and development of novel therapeutic strategies
  • Development of blood-based exosome biomarkers for renal cell carcinoma
  • Investigation of the effects of probiotics on the urinary microbiome in patients with ileal conduit urinary diversion
  • Development of novel biomarkers for non–muscle-invasive bladder cancer based on urinary exfoliated cells
  • Development of novel therapeutic strategies for neuroendocrine prostate cancer

BIBLIOGRAPHY

2025
  1. Fukui T, Okasho K, Okuno Y, Fujiwara M, Akamatsu S. et al. “A highly sensitive screening system to evaluate the reversibility of neuroendocrine prostate cancer to prostate adenocarcinoma.” Cancer Med. 14(5):e70047. doi: 10.1002/cam4.70047. 2025
  2. Takikawa M, Nakano A, Krishnaraj J, Tabata Y,Ohki R et al. Extrinsic induction of apoptosis and tumor suppression via the p53-Reprimo-Hippo-YAP/TAZ-p73 pathway Proc Natl Acad Sci U S A. 2025 Feb 11;122(6):e2413126122. doi: 10.1073/pnas.2413126122. 2025
  3. Nagumo Y, Hattori K, Kimura T, Sekino Y, Nishiyama H. et al. Combined Molecular Subclass and Immune Phenotype Correlate to Atezolizumab Plus Radiation Therapy Response in Invasive Bladder Cancer: BPT-ART Phase 2 Study. Int J Radiat Oncol Biol Phys. 122(1):168-180. 2025
  4. Kato M, Sato H, Naito Y, Akamatsu S, Tsuzuki T. et al. “Prospective observational study on the relationships between genetic alterations and survival in Japanese patients with metastatic castration-sensitive prostate cancer: the impact of IDC-P.” Int J Clin Oncol. doi: 10.1007/s10147-025-02707-3. 2025
  5. Zennami K, Nukaya T, Ishikawa K, Tomozawa S, Shiroki R et al. Exposure to ileal feces with frailty-associated dysbiosis elevates gastrointestinal complication risk after intracorporeal urinary diversion Sci Rep.;15(1):22333. doi: 10.1038/s41598-025-07932-4. 2025
  6. Latarani M, Pucci P, Eccleston M, Akamatsu S, Crea F. et al. “EZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell lines.” Epigenomics 17(3):145-154. doi: 10.1080/17501911.2025.2453419. 2025
  7. Sakatani T, Sumiyoshi T, Kita Y, Akamatsu S, Kobayashi T. et al. “Clinical Utility of Serial Circulating Tumor DNA Analysis as a Minimally Invasive Biomarker in Advanced Urothelial Cancer.” JCO Precis Oncol. e2400472. doi: 10.1200/PO-24-00472. Epub 2025
2024
  1. Owaki T, Iida T, Miyai Y, Akamatsu S, Enomoto A. et al. “Synthetic retinoid-mediated preconditioning of cancer-associated fibroblasts and macrophages improves cancer response to immune checkpoint blockade.” Br J Cancer. 131(2):372-386. doi: 10.1038/s41416-024-02734-3. 2024
  2. Matsuoka T, Sugiyama A, Miyawaki Y, Akamatsu S, Nakamura E. et al. “Newly developed preclinical models reveal broad-spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide.” Cancer Sci. 115(1):283-297. 2024
2023
  1. Nomura M, Ohuchi M, Sakamoto Y, Akamatsu S, Tanuma N. et al. “Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma.” Nat Commun. 14(1):8095. 2023
  2. Takeda M, Sakamoto H, Shibasaki N, Ogawa O, Akamatsu S. et al. “Extracellular vesicles secreted from bone metastatic renal cell carcinoma promote angiogenesis and endothelial gap formation in bone marrow in a time-dependent manner in a preclinical mouse model.” Front Oncol. 13:1139049. eCollection 2023

MESSAGE

Call for graduate students

 We welcome graduate students, who are interested in clinical, basic, or both researches, to our department.

Back to top of page